OSI-027 Chemical Properties

Melting point:

>149°C (subl.)

Density 

1.59

storage temp. 

Hygroscopic, -20°C Freezer, Under inert atmosphere

solubility 

DMSO (Slightly)

pka

4.44±0.10(Predicted)

form 

Solid

color 

Pale Beige to Light Beige

OSI-027 Usage And Synthesis

Description

The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin ) and regulate different pathways. OSI-027 is an inhibitor of the catalytic site of mTOR and, as a result, inhibits both mTORC1 and mTORC2 (IC₅₀s = 22 and 65 nM, respectively). It is selective for mTOR over phosphatidylinositol 3-kinase isoforms and DNA protein kinase. OSI-027 prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells at 10 μM. OSI-027 is effective in vivo, blocking the phosphorylation of targets of mTORC1 and mTORC2 and suppressing tumor growth in several different human xenograft models.

Uses

OSI-027 is a kinase inhibitor with anti-tumor activity, used in treatment of breast cancer.

Definition

ChEBI: 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid is a member of indoles.

target

mTORC

References

[1] bhagwat s v, gokhale p c, crew a p, et al. preclinical characterization of osi-027, a potent and selective inhibitor of mtorc1 and mtorc2: distinct from rapamycin. molecular cancer therapeutics, 2011, 10(8): 1394-1406.

OSI-027(936890-98-1)Related Product Information

• 3'-Amino-4'-methoxyacetanilide
• p-Anisidine-3-sulfonic acid
• trans-4-Aminocyclohexanol
• AZD-8055
• VE 822
• Ibrutinib
• LY 294002 HYDROCHLORIDE
• Rapamycin
• BEZ235 (NVP-BEZ235, Dactolisib)